Caricamento...
Xenopus‐derived glucagon‐like peptide‐1 and polyethylene‐glycosylated glucagon‐like peptide‐1 receptor agonists: long‐acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities
BACKGROUND AND PURPOSE: Incretin‐based therapies based on glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments of type 2 diabetes. Abundant research has focused on the development of long‐acting GLP‐1 receptor agonists. However, all GLP‐1 receptor agonists in clinical use or de...
Salvato in:
| Pubblicato in: | Br J Pharmacol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5773971/ https://ncbi.nlm.nih.gov/pubmed/29171021 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14107 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|